Not yet recruiting
Exclusion of Left Atrial Appendage Thrombus in Emergency Department Patients With Atrial Fibrillation Undergoing CT to Assess for Pulmonary Embolus: A Feasibility Study
NCT07647939· Northwell Health· Source
Contact: Tabetha Garver-Mosher
Recruiting
A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease
NCT07214376· Pulnovo Medical, Inc.· Source
Contact: Perwaiz Meraj
Recruiting
FORWARD: Functional Outcomes in Real-World Treatment And Revascularization of Non-dominant and Distal M2 Occlusions
NCT07749170· Penumbra Inc.· Source
Contact: Madeline Turtle
Recruiting
Single Chamber Atrial Leadless Pacing for Isolated Sinus Node Dysfunction
NCT07638995· Northwell Health· Source
Contact: Salome Elia Reddy
Recruiting
Trans-arterial Embolization for the Treatment of Facet Pain Due to Facet Arthropathy
NCT06965452· Northwell Health· Source
Contact: Betsy Moclair
Recruiting
Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
NCT06779630· Teleflex· Source
Contact: BIOFLOW-48 Project Manager
Active, not recruiting
TECTONIC CAD IVL IDE Study
NCT06885177· Abbott Medical Devices· Source
Active, not recruiting
ARIADNE Clinical Trial
NCT06747091· Stavros E Mountantonakis· Source
Active, not recruiting
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
NCT06456463· Phase 2· Stemline Therapeutics, Inc.· Source
Recruiting
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
NCT06526195· Abbott Medical Devices· Source
Contact: Salome Reddy
Recruiting
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
NCT06317649· Phase 2· National Cancer Institute (NCI)· Source
Contact: Erin Jou (principal investigator)
Recruiting
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
NCT05554406· Phase 2· National Cancer Institute (NCI)· Source
Contact: David Chitty (principal investigator)
Recruiting
SuperSaturated Oxygen Comprehensive Observational Registry
NCT06438315· TherOx· Source
Contact: Rajiv Jauhar, MD
Active, not recruiting
TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)
NCT06137807· P+F Products + Features USA Inc.· Source
Recruiting
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
NCT05564390· Phase 2· National Cancer Institute (NCI)· Source
Contact: David Chitty (principal investigator)
Active, not recruiting
A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)
NCT06347159· Phase 2· Edgewise Therapeutics, Inc.· Source
Recruiting
Strategy for Improving Stroke Treatment Response
NCT05948566· Phase 2· Translational Sciences, Inc.· Source
Contact: Rohan Arora
Recruiting
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06152575· Phase 3· Pfizer· Source
Active, not recruiting
Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia
NCT05303792· Phase 2· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response
NCT05610163· Phase 2/3· Alliance for Clinical Trials in Oncology· Source
Recruiting
Accuracy of Doppler Ultrasound Versus Manual Palpation of Pulse in Cardiac Arrest
NCT05558228· Northwell Health· Source
Contact: Timmy Li, PhD
Recruiting
Elucidating the Temporality of Structural and Functional Connectivity Changes in Essential Tremor After Successful Deep Brain Stimulation to the Dentato-rubro-thalamic Tract
NCT04758624· Northwell Health· Source
Contact: Albert Fenoy
Active, not recruiting
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial
NCT03496883· Phase 3· Joseph Broderick, MD· Source
Active, not recruiting
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
NCT05198674· Medtronic Vascular· Source
Active, not recruiting
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
NCT04609046· Phase 1· National Cancer Institute (NCI)· Source
Enrolling by invitation
ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
NCT05368038· Albert Einstein College of Medicine· Source
Active, not recruiting
TRISCEND II Pivotal Trial
NCT04482062· Edwards Lifesciences· Source
Active, not recruiting
Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer
NCT04559139· Phase 2/3· ECOG-ACRIN Cancer Research Group· Source
Recruiting
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
NCT04031677· Phase 3· European Organisation for Research and Treatment of Cancer - EORTC· Source
Contact: EORTC HQ
Active, not recruiting
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
NCT04340141· Phase 3· Alliance for Clinical Trials in Oncology· Source
Recruiting
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NCT04251052· NRG Oncology· Source
Contact: Marina Frimer (principal investigator)
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis
NCT04221477· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
Personalized Therapy Study - HFRS (TriageHF) Post Approval Study
NCT04489225· Medtronic· Source
Active, not recruiting
Personalized Therapy Study - Intrinsic Antitachycardia Pacing Post-Approval Study (iATP PAS)
NCT04496518· Medtronic· Source
Recruiting
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046· Phase 3· Yale University· Source
Contact: Rohan Arora, MD
Active, not recruiting
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
NCT03984448· Phase 2/3· National Cancer Institute (NCI)· Source
Active, not recruiting
Brain Oxygen Optimization in Severe TBI, Phase 3
NCT03754114· University of Michigan· Source
Recruiting
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
NCT03739814· Phase 2· National Cancer Institute (NCI)· Source
Contact: Bradley H. Goldberg (principal investigator)
Active, not recruiting
Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
NCT03701308· Phase 2/3· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
NCT03737981· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Medtronic Transcatheter Aortic Valve Replacement (TAVR) Low Risk Bicuspid Study
NCT03635424· Medtronic Cardiovascular· Source
Active, not recruiting
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
NCT03269669· Phase 2· National Cancer Institute (NCI)· Source
Recruiting
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
NCT03150693· Phase 3· Alliance for Clinical Trials in Oncology· Source
Contact: Bradley H. Goldberg (principal investigator)
Active, not recruiting
Personalized Therapy Study - Attain Stability Quad Post-Approval Study
NCT04024943· Medtronic· Source
Recruiting
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
NCT02523014· Phase 2· Alliance for Clinical Trials in Oncology· Source
Contact: Priscilla Brastianos, MD
Active, not recruiting
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT02465060· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
NCT02143414· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
NCT02003222· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT02048813· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
NCT01886872· Phase 3· National Cancer Institute (NCI)· Source
Showing 50 of 56.